Kiora Pharmaceuticals (KPRX) Operating Expenses (2014 - 2026)

Kiora Pharmaceuticals (KPRX) has reported Operating Expenses for 13 consecutive years, with $2.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses fell 7.61% year-over-year to $2.2 million; the trailing twelve-month figure through Jun 2026 stood at $12.8 million (up 17.76% YoY), and the FY2025 full-year result was $12.8 million, up 11.48% from the prior year.
• Operating Expenses slipped to $2.2 million in Q2 2026 per KPRX's latest filing, from $2.5 million in the prior quarter.
• Across five years, Operating Expenses topped out at $7.3 million in Q4 2025 and bottomed at $794437.0 in Q3 2025.
• Historically, Operating Expenses has averaged $3.0 million across 5 years, with a median of $2.6 million in 2024.
• The widest YoY moves for Operating Expenses: up 185.03% in 2025, down 77.95% in 2025.
• Over 5 years, Operating Expenses stood at $2.6 million in 2022, then dropped by 19.6% to $2.1 million in 2023, then climbed by 21.05% to $2.6 million in 2024, then surged by 185.03% to $7.3 million in 2025, then sank by 69.72% to $2.2 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $2.2 million, $2.5 million, and $7.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.